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Morphologic distinction of Müllerian carcinomas from non-Müller-
ian carcinomas in effusion specimens by cytomorphology alone
can be diagnostically challenging. Therefore, immunohistochemical
adjuncts can be useful in differentiating Müllerian from non-Mül-
lerian metastases. In this study, we evaluated the expression of
PAX8 and PAX2 in malignant effusions collected from patients
with known Müllerian and non-Müllerian carcinomas. Sections
from cell blocks prepared from 152 effusion specimens (54 and 98
cases representing metastases from Müllerian and non-Müllerian
primaries, respectively) were immunostained with rabbit polyclo-
nal antibodies against PAX8 and PAX2. Immunopositivity was
defined as the presence of strong nuclear staining in at least 25%
of the tumor cells. Fifty-two (96%) and 13 (24%) of the 54 Mül-
lerian carcinomas were positive for PAX8 and PAX2, respectively.
PAX8 positivity was seen in only four (4%) of 98 non-Müllerian
carcinomas; these represented metastasis from a large cell neuro-
endocrine lung carcinoma, papillary thyroid carcinoma, renal cell
carcinoma, and acinic cell carcinoma of the parotid gland. PAX2
positivity was not seen in any of the non-Müllerian carcinomas.
The results demonstrate that both PAX8 and PAX2 are highly spe-
cific markers for metastatic Müllerian carcinomas in cell block
preparations from effusion specimens (96% and 100%, respec-
tively). PAX8, however, is more sensitive than PAX2 in identifying
Müllerian carcinomas in fluids (96% versus 24%). Overall, immu-
nohistochemistry for PAX8 and PAX2 represent diagnostically
useful adjuncts in identifying a Müllerian carcinoma as a source
of a malignant effusion. Diagn. Cytopathol. 2011;39:651–656.
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Metastatic carcinoma represents a common cause of fluid
accumulation in the pleural, peritoneal, and pericardial
spaces. In some cases, there is a known cancer history at
the time a malignant effusion is diagnosed. Nonetheless,
in other cases, a malignant effusion is diagnosed in the
absence of a known primary malignancy.1 Occasionally,
cytologic evaluation of an effusion specimen can uncover
the presence of a distinct primary in the setting of a pre-
viously documented cancer history. It is therefore impor-
tant to determine or confirm a metastasis from a particular
primary site as this will yield clinically useful information
about the nature and extent of disease and facilitate the
tailoring of optimal treatment regimens.2 Because of over-
lapping cytomorphologic features of carcinomatous effu-
sions by various primaries,3 confident identification of a
primary can be difficult by cytomorphologic evaluation
alone. Therefore, immunohistochemistry is often em-
ployed to gain insight into the primary site.4–6
Malignancies of the female gynecological (Müllerian)
tract often present initially as ascites and effusions. The
accurate diagnosis of malignant effusions resulting from
metastatic Müllerian carcinomas is essential as specific
chemotherapeutic regimens are used to treat distinct Mül-
lerian carcinomas. For instance, high-grade serous carci-
nomas are typically treated with combination chemother-
apy consisting of carboplatin and paclitaxel.7 Furthermore,
because these cancers usually present at an advanced
stage, neoadjuvant chemotherapy with subsequent debulk-
ing surgery can be considered as a treatment option in
cases where the extent of disease is deemed unresectable
at initial presentation.8 Also, the development of an effu-
sion can indicate recurrence of malignancy after treat-
ment. In both contexts, cytologic evaluation of effusions
represents a minimally invasive method to obtain a spe-
cific pathologic diagnosis; accurately diagnosing a metas-
tasis from a Müllerian carcinoma in effusions can lead to
appropriate, prompt treatment.
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The most common Müllerian carcinoma to present in
effusions is serous carcinoma which is known to originate
in the ovary, fallopian tube, peritoneum, and endome-
trium,9 the majority of which are high-grade and manifest
as single cells or small clusters in fluids. This cytomor-
phologic presentation can overlap with carcinomas origi-
nating from other primary sites such as breast, lung, and
pancreas.3,10 Furthermore, in some cases, individual tumor
cells can be difficult to distinguish from reactive mesothe-
lial cells. Thus, especially in cases where the primary site
of malignancy is unknown, diagnosing a malignant effu-
sion and subsequently distinguishing a Müllerian from a
non-Müllerian malignancy with certainty by cytomorphol-
ogy alone can be challenging.
Immunohistochemical adjuncts have been previously
reported in the diagnosis of Müllerian carcinomas. Nota-
bly, high-grade serous carcinomas are often immunoreac-
tive for p5311 and WT-1.12,13 However, mesothelial cells
are also immunoreactive for WT-1 and reactive mesothe-
lium can occasionally be p53-positive14 thereby rendering
immunohistochemical stains for WT-1 and p53 difficult to
interpret in some cases. Furthermore, immunoreactivity
for ER and PR can support Müllerian origin; however,
positivity for these hormone receptors can often be seen
in the context of malignant effusions secondary to meta-
static breast carcinomas.15
Recently the transcription factors, PAX2 and PAX8,
have been reported to be expressed in Müllerian-derived
epithelium such as the fallopian tube epithelium.16–18 Fur-
thermore, studies have shown that their expression is
maintained in malignant tumors derived from this epithe-
lium. For instance, Roh et al. have reported strong,
diffuse PAX8 expression in the vast majority of serous
carcinomas.19 Furthermore, Tong et al. also reported that
PAX2 is positive in a significant proportion of Müllerian
carcinomas.18 In addition, Nonaka et al. and Chivukula et
al. investigated the utility of PAX8 and PAX2, respec-
tively, to differentiate ovarian carcinomas from breast car-
cinomas in surgically resected specimens.20,21
To date, there are no reports that investigate the utility
of PAX2 and PAX8 immunohistochemistry in effusion
specimens. Therefore, we sought to investigate the diag-
nostic utility of immunohistochemistry for PAX2 and
PAX8 as adjuncts to cytology in the identification and
differentiation of Müllerian carcinomas from non-Müller-
ian carcinomas in effusions.
Methods
After approval was obtained from the Institutional Review
Board at University of Michigan, the electronic pathology
database along with surgical pathology reports, clinical
notes, and radiology reports were examined to identify
patients in whom carcinomatous effusions (pleural, perito-
neal, and pericardial) from a known primary site were
diagnosed from 2000 to 2003. The slides prepared from
each effusion specimen were reviewed and cases in which
sufficient tumor was present in the formalin-fixed, paraf-
fin-embedded cell block preparations were identified by
examining recut, Hematoxylin and Eosin (H&E) stained
slides. A total of 152 malignant effusions, one from each
patient, were included in this study (Table I).
Immunohistochemistry was performed using the DAKO
Autostainer (DAKO, Carpinteria, CA) using DAKO
LSAB+ and 3,30-diaminobenzidine as the chromogen. For
each case, 4-lm unstained sections were prepared from
the cell blocks, deparaffinized, and immunostained after
antigen retrieval in 0.01M citrate buffer, pH 6.0 (DAKO,
Carpinteria, CA). Immunohistochemistry was performed
using the rabbit polyclonal anti-PAX2 (1:100 dilution;
Invitrogen, Camarillo, CA) and rabbit polyclonal anti-
PAX8 (1:200 dilution; Protein Tech, Chicago, IL) anti-
bodies along with appropriate controls. The EnVision+
System for use with rabbit primary antibodies (DAKO,
Table I. Primary Sites of Malignancy in the 152 Patients With
Carcinomatous Effusions
Primary tumor # Patients # PAX8(+) # PAX2(+)
Ovary/fallopian tube
Serous carcinoma 34 32 7
Carcinosarcoma 2 2 0
Clear cell carcinoma 2 2 1
Endometrioid 1 1 0
Poorly differentiated carcinoma 3 3 1
Primary Peritoneal
Serous carcinoma 7 7 2
Poorly differentiated carcinoma 1 1 1
Endometrium
Serous carcinoma 3 3 0
Carcinosarcoma 1 1 1
Lung
Adenocarcinoma 20 0 0
Squamous cell carcinoma 3 0 0
Non-small cell carcinoma 8 0 0
Large cell neuroendocrine carcinoma 2 1 0
Small cell carcinoma 1 0 0
Breast
Ductal carcinoma 25 0 0
Lobular carcinoma 2 0 0
Colloid carcinoma 1 0 0
Gastroesophageal
Adenocarcinoma 15 0 0
Pancreaticobiliary
Adenocarcinoma 9 0 0
Colon
Adenocarcinoma 6 0 0
Appendix
Adenocarcinoma 1 0 0
Larynx
Adenoid cystic carcinoma 1 0 0
Bladder
Urothelial cell carcinoma 1 0 0
Thyroid
Papillary thyroid carcinoma 1 1 0
Kidney
Renal cell carcinoma, clear cell type 1 1 0
Parotid
Acinic cell carcinoma 1 1 0
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Carpinteria, CA) was used as the secondary antibody.
Each immunostained slide was reviewed blindly by two
reviewers (WW and MHR) and strong nuclear staining
for PAX2 and PAX8 in at least 25% of the tumor cells
was considered as a positive result. The presence or
absence of staining of background mesothelial cells and
histiocytes was also recorded in each case.
Results
A total of 152 patients with metastatic carcinomatous
effusions from a known primary site were identified and
represented the source of material utilized in this study
(Table I). Fifty-four (36%) patients were diagnosed with
a malignant effusion secondary to a Müllerian primary
malignancy (ovary, fallopian tube, primary peritoneal, and
endometrium); the majority of these (44 of 54; 81%) rep-
resented high-grade serous carcinomas. The remainder of
the Müllerian primary malignancies consisted of: three
carcinosarcomas; two clear cell carcinomas; one high-
grade endometrioid carcinoma; and four poorly differenti-
ated carcinomas. The lung represented the most common
non-Müllerian primary tumor that metastasized to fluids
(34 of 152; 22%): 20 adenocarcinomas; three squamous
cell carcinomas; eight non-small cell carcinomas; two
large cell neuroendocrine carcinomas; and one small cell
carcinoma. Breast primaries represented the next most fre-
quent non-Müllerian primary source of malignant effusions
(28 of 152; 18%): 25 ductal carcinomas, two lobular carcino-
mas, and one colloid carcinoma. In 15 (10%), nine (6%), six
(4%), and one case (1%), the malignant effusions were sec-
ondary to metastases from upper gastrointestinal, pancreati-
cobiliary, colonic, and appendiceal primaries, respectively.
The remaining 5 of 152 (3%) primary malignancies to give
rise to carcinomatous effusions consisted of: papillary thy-
roid carcinoma; renal cell carcinoma, clear cell type; urothe-
lial cell carcinoma; adenoid cystic carcinoma; and acinic cell
carcinoma. Results for PAX8 and PAX2 immunohistochem-
istry for the cases are summarized in Table I.
Immunohistochemistry revealed strong nuclear immunore-
activity for PAX8 in at least 25% of the tumor cells in 56
cases. Specifically, over 50% of the tumor cells were positive
in 52 cases and between 25% and 50% of the tumor cells
were positive in the remaining four. Fifty-two of the
PAX8(+) malignant effusions represented metastases from
Müllerian primaries (Table II), which included serous carci-
nomas, carcinosarcomas, clear cell carcinomas, and the one
case of endometrioid carcinoma (Fig. 1). In one additional
case of serous carcinoma, only rare tumor cells (*1% of the
total tumor cell population) were highlighted by the PAX8
immunostain; this case was scored as negative, however, as
the vast majority of the tumor cells were negative for PAX8.
Of note, in each of the carcinosarcoma cases, the sarcoma-
tous component was not present in the malignant effusion.
Overall, the sensitivity for PAX8 in detecting Müllerian
malignancies in fluids was 96% (52/54). The four remaining
PAX8(+) cases represented malignant effusions secondary to
non-Mullerian primaries including: a large cell neuroendo-
crine carcinoma of the lung; papillary thyroid carcinoma;
and an acinic cell carcinoma of the parotid gland; and a renal
cell carcinoma, clear cell type (Fig. 2). In the remaining non-
Mullerian carcinomas examined, none of the tumor cells
were positive for PAX8. Overall, four of the 98 non-Müller-
ian malignant effusions were positive for PAX8; thus, the
specificity of PAX8 for identifying Müllerian malignancies
was 96% (Table II).
Next, immunohistochemistry for PAX2 revealed strong
nuclear PAX2 immunoreactivity in 13 cases (Table I). All
13 cases were malignant effusions secondary to Müllerian
primaries (Table II). In eight cases, over half of the tumor
cells were highlighted by PAX2 and 25–50% of the tumor
cells were PAX2(+) in the remaining five. The remainder
of the Müllerian carcinomas and all of the non-Müllerian
carcinomas were completely negative for PAX2. Overall,
the sensitivity for PAX2 in detecting Müllerian malignan-
cies in effusions was 24% (13/54). Because none of the
non-Müllerian tumors were PAX2(+), the specificity of
PAX2 for identifying Müllerian malignancies in fluids
was 100%. Of note, all 13 PAX2(+) tumors were also
PAX8(+). Finally, in every case, PAX8 and PAX2 immu-
nohistochemistry failed to highlight the background meso-
thelial cells and histiocytes in this study (Fig. 1).
Discussion
Recently, the expression of the transcription factors,
PAX2 and PAX8, have been reported in carcinomas of
the female genital tract including serous, endometrioid,
and clear cell carcinomas.18,20,21 As there are no studies
to date that have investigated the application of PAX2
and PAX8 immunohistochemistry to effusions, we sought
to determine the expression of these two markers in Mül-
lerian carcinomas in fluid specimens. In this study, we
discovered that the majority of metastatic carcinomas of
Müllerian origin were immunoreactive for PAX8 in effu-
sions with high sensitivity (96%). Specifically, in all but
two serous carcinomas and in all of the metastatic carci-
nomas originating from carcinosarcomas, clear cell carci-
nomas, and endometrioid carcinoma, PAX8 immunoreac-
tivity was seen in at least 25% of the tumor cells. This is
concordant with the findings by Bowen et al. which
showed a high frequency of PAX8 immunoreactivity in
Table II. Sensitivity and Specificity of PAX8 and PAX2 as
Immunohistochemical Markers for Müllerian Carcinomas in Effusions
PAX8 (+) PAX2 (+)
Müllerian Carcinoma (n ¼ 54) 52 (96%) 13 (24%)
Non-Müllerian Carcinoma (n ¼ 98) 4 (4%) 0 (0%)
Sensitivity 96% 24%
Specificity 96% 100%
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various subtypes of ovarian carcinomas.16 Furthermore,
our results are complementary to those reported by
Davidson et al. who applied gene expression profiling to
malignant effusions; they reported increased gene expres-
sion of PAX8 in serous carcinomas in fluid specimens.22
Next, we sought to determine whether PAX8 immuno-
positivity was specific for Müllerian carcinomas by exam-
ining the expression of PAX8 in non-Müllerian carcinom-
atous effusions in parallel. Lung, breast, gastrointestinal,
and pancreaticobiliary carcinomas represent common eti-
ologies for malignant effusions.3 We found that 100% of
breast, gastrointestinal, and pancreaticobiliary carcinomas
and 97% of lung carcinomas in our study were negative
for PAX8. Of note, all 20 of the lung adenocarcinomas,
the subtype of lung carcinoma most likely to mimic
Müllerian adenocarcinoma, were not immunoreactive for
PAX8. These results are consistent with prior reports by
Nonaka and colleagues that PAX8 is a highly specific
marker for distinguishing Müllerian carcinomas from
these non-Müllerian carcinomas.20,23 PAX8 immunoreac-
tivity in effusions was seen in only four non-Müllerian
carcinomas including metastatic papillary thyroid carci-
noma and renal cell carcinoma. This can be reconciled in
light of the finding that PAX8 is expressed in thyroid fol-
licular epithelium and renal tubular epithelium as well as
thyroid carcinomas and renal cell carcinomas.23,24 It
should be noted that carcinomas of thyroid and renal ori-
gin rarely metastasize to fluids10 explaining the low num-
ber of these malignant effusions in our study population;
nonetheless, our results confirm that PAX8 can be useful
in confirming the presence of metastatic carcinomas from
the thyroid and kidney in effusions. We also found one
case each of a large cell neuroendocrine lung carcinoma
and an acinic cell carcinoma of the salivary gland to be
Fig. 1. PAX8 and PAX2 highlights metastatic Müllerian carcinomas in effusions. A–C: Metastatic serous carcinoma in cell block sections of pleural
fluid, 3600. D–F: Metastatic clear cell carcinoma in cell block sections of peritoneal fluid, 3600. G,H: Metastatic endometrioid carcinoma in a cell
block prepared from a malignant peritoneal effusion, 3400. H&E stained sections are shown in A, D, and G, PAX8 immunostains in B, E, and H, and
PAX2 immunostains in C, F, and I. B,C: Strong nuclear positivity for PAX8 and PAX2 are observed in the serous carcinoma cluster on the left indi-
cated by the arrow; the background mesothelial cells are not immunoreactive for PAX8 and PAX2. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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immunoreactive for PAX8. These also represent malig-
nancies that seldomly metastasize to effusions and
because the expression of PAX8 in these malignancies
have not been studied in detail, additional studies will be
required to determine the frequency of PAX8 positivity in
these cancers. Nonetheless, our results overall demonstrate
that PAX8 is a highly sensitive and specific marker for
metastatic carcinomas of Müllerian origin in fluids.
We sought to ascertain the sensitivity and specificity of
PAX2 as a marker for Müllerian carcinomas. In contrast
to PAX8, PAX2 was only positive in 24% of the Müller-
ian carcinomas in this study. This contrasts with the find-
ings by Tong et al. who showed that over half of serous
carcinomas are immunoreactive for PAX2.18 Nonetheless,
our results can be reconciled in light of the more recent
finding that the proportion of high-grade serous carcino-
mas that express PAX2 at the mRNA and protein level is
significantly less than that of low grade serous carcino-
mas.25 It should be noted that none of the serous carcino-
mas in our study were low grade. Of note, PAX2 expres-
sion has been found in 61–85% of renal cell carcino-
mas.26,27 Although our one case of metastatic renal cell
carcinoma was negative for PAX2, it is likely that others
may be PAX2 positive.
Finally, the cytomorphologic patterns of malignant mes-
othelioma in effusions can mimic those of carcinomas,
especially those of Müllerian origin. Although the expres-
sion of PAX8 in mesothelioma is not well characterized,
the majority of mesotheliomas appear to be negative for
PAX2. Specifically, one previous study demonstrated that
only two of 54 mesothelioma cases were immunoreactive
for PAX2.18 Although additional studies examining the
expression of PAX8 and PAX2 in mesotheliomas are
needed, a panel of immunostains utilizing other antibodies
such as those directed against calretinin, MOC-31, BerEP4,
B72.3, and Leu-M1 can be helpful in distinguishing Mül-
lerian carcinomas from mesotheliomas in effusions.6
In conclusion, our study demonstrates that both PAX8
and PAX2 are specific markers for identifying metastatic
Müllerian carcinomas in effusions (96% and 100%,
respectively). PAX8, however, is a more sensitive marker
for Müllerian carcinomas than PAX2 (96% versus 24%).
Nonetheless, we demonstrate the diagnostic utility of
PAX8 and PAX2 in identifying and distinguishing carci-
nomatous effusions of Müllerian origin from those of
non-Müllerian origin.
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